TY  - JOUR
AU  - Gray, Jhanelle E
AU  - Villegas, Augusto
AU  - Daniel, Davey
AU  - Vicente, David
AU  - Murakami, Shuji
AU  - Hui, Rina
AU  - Kurata, Takayasu
AU  - Chiappori, Alberto
AU  - Lee, Ki Hyeong
AU  - Cho, Byoung Chul
AU  - Planchard, David
AU  - Paz-Ares, Luis
AU  - Faivre-Finn, Corinne
AU  - Vansteenkiste, Johan F
AU  - Spigel, David R
AU  - Wadsworth, Catherine
AU  - Taboada, Maria
AU  - Dennis, Phillip A
AU  - Özgüroğlu, Mustafa
AU  - Antonia, Scott J
PY  - 2019
DO  - 10.1016/j.jtho.2019.10.002
UR  - http://hdl.handle.net/10668/14900
T2  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
AB  - In the phase 3 PACIFIC study of patients with unresectable stage III NSCLC without progression after chemoradiotherapy, durvalumab demonstrated significant improvements versus placebo in the primary end points of progression-free survival (hazard...
LA  - en
KW  - Durvalumab
KW  - NSCLC
KW  - Overall survival
KW  - PACIFIC
KW  - Three-year update
KW  - Antibodies, Monoclonal
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Chemoradiotherapy
KW  - Humans
KW  - Lung Neoplasms
KW  - Neoplasm Staging
TI  - Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
TY  - research article
VL  - 15
ER  -